Building on the promising findings from Fato et al. and the limited availability of disease-modifying therapies for preeclampsia, we aimed to contribute to the growing body of evidence supporting CNP as a potential drug target for preeclampsia. The gene discussed is CNP; the disease is preeclampsia.